MedEquities Realty Trust (MRT) Stock

Marti surpassed 1.6 million riders and 255,000 drivers, achieving 15% ride growth in six months. Estimated at $9–$12 billion TAM, with Marti positioned to capture a $2 billion revenue potential. Marti's driver subscription model implies a 10% effective take rate, offering $800 million initial revenue potential.

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced the election of Alex Spiro to its Board of Directors as a Class II director at the Company's 2024 annual general meeting of shareholders. In addition to being a well known litigator and partner at Quinn Emanuel Urquhart & Sullivan LLP, Mr. Spiro serves as Chairman of Glassbridge Enterprises and is a board member and strategic advisor to a.

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of December 15, 2024, Marti's ride-hailing service has reached 1.61 million riders and 255 thousand registered drivers, exceeding the December 31, 2024 targets of 1.60 million riders and 245 thousand registered drivers. Marti's number of ride-hailing riders grew 15% from September 30, 2024 to December 15, 2024. The number of registere.

Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule Additional MRT-2359 Phase 1/2 study clinical results, including biomarker and activity data, anticipated in Q1 2025 BOSTON, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered and developed by Monte Rosa Therapeutics.

ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app, Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) announces its expectation to reach positive free cash flow in 2025 and presents 2025 guidance. After two years of investing in growing its ride-hailing business, Marti announced in October 2024 that it has begun monetizing its ride-hailing service. As the only at scale ride-hailing operator in the country, together with the monetization of its ride-hailing se.

SINGAPORE, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the facilities management sector, through its subsidiary, today announced that the Company had completed the sale and successful deployment of 89 autonomous cleaning robots across Singapore, marking the largest robotic fleet in the land transport sector with rail operator SMRT Trains.

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced that it has appointed Deniz Terlemez as its new Interim Chief Financial Officer (“CFO”), effective November 1, 2024. Deniz Terlemez succeeds Oguz Erkan, the Company's former CFO. Mr. Terlemez served as the Company's Finance Director before his appointment as Interim CFO. “We would like to thank Oguz Erkan for his integral contributions to the.

ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced an amendment to extend its share repurchase program. The Company's Board of Directors (the “Board”) authorized a six month extension to its share repurchase program under which the Company may repurchase up to $2.5 million of its outstanding Class A ordinary shares until April 9, 2025. The share repurchase program was originally initiated on Ja.

Marti Technologies, Inc. (NYSE:MRT ) Q2 2024 Earnings Conference Call September 30, 2024 8:30 AM ET Company Participants Oguz Alper Oktem - Founder and Chief Executive Officer Cankut Durgun - Co-Founder and President Conference Call Participants Brett Knoblauch - Cantor Fitzgerald Poe Fratt from - Global Partners Operator Hello, everyone, and thank you for joining us for Marti's First Half 2024 Conference Call. Before we begin, I'd like to mention that today's presentation and earnings release are available on Marti's Investor Relations website at ir.marti.tech.